Product label
Regulatory context; not efficacy evidence
Patients meeting the current Pregnyl label for selected fertility/endocrine indications.
Reported findings. Approved product evidence is indication and preparation specific.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Label includes ovarian hyperstimulation, thromboembolic and hypersensitivity risks.
Limits. This label does not approve research-market hCG or use for weight loss.
Preparation: Pregnyl urinary-derived chorionic gonadotropin Route: intramuscular
Read original source ↗Editorial review 2026-10-09. Clinician review pending.